Andere talen RedHill Biopharma Ltd. Deutsche Boerse AG

Aandelen

2RH0

US7574682024

Beurs gesloten - Deutsche Boerse AG Andere beurzen 08:10:55 16-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,3205 ^EUR	+1,10%		+4,57%	-74,76%

09/07	Redhill Biopharma Ltd. Beëindigt licentieovereenkomst voor Aemcolo	CI
06/06	RedHill Biopharma Ltd. kondigt ontslag aan van Alla Felders als lid van de raad van bestuur	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

RedHill Biopharma Terminates License Agreement for Aemcolo	10/07
Redhill Biopharma Ltd. Terminates License Agreement for Aemcolo	09/07
RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board	06/06
RedHill Biopharma : Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - Form 6-K	03/06
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	06/05
RedHill Biopharma : Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - Form 6-K	06/05
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035	06/05
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	06/05
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K	24/04
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study	24/04
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights	09/04
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price	03/04
RedHill Biopharma Ltd. cancelled the transaction announced on March 8, 2023	28/03
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection	11/03
RedHill Biopharma : Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Form 6-K	05/03
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs	05/03
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs	05/03
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis, New Publication	21/02
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences	20/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen RedHill Biopharma Ltd. Deutsche Boerse AG

Aandelen

2RH0

US7574682024

Andere talen

Filters